Rare Neuroimmune Disorders in the Literature: Recent Research Publications

2024 ISSUE 1

Below is a compilation of recently published research publications relating to rare neuroimmune disorders:

Sato K, Watanabe R, Ito I, Imadome KI, Sumi M, Kobayashi H. Successful Treatment of Epstein-Barr Virus Reactivation-associated Transverse Myelitis Following Herpes Zoster with Intravenous Rituximab in a Cord Blood Transplant Recipient. Intern Med. Published online February 1, 2024. doi:10.2169/internalmedicine.2874-23

Rocchi C, Forcadela M, Kelly P, et al. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis. Mult Scler. Published online January 23, 2024. doi:10.1177/13524585231221664

Simon D. Severe Mimic of Transverse Myelitis – Spontaneous Non-Traumatic Intramedullary Hematomyelia: A Case Report. Neurohospitalist. 2024;14(1):83-86. doi:10.1177/19418744231196931

Dhakal B, Bogati K, Baniya S, et al. Longitudinally extensive transverse myelitis, a disabling disorder with a good prognosis: a case series from Nepal. Ann Med Surg (Lond). 2023;86(1):252-256. Published 2023 Nov 27. doi:10.1097/MS9.0000000000001537

Whitehouse ER, Lopez A, English R, et al. Surveillance for Acute Flaccid Myelitis – United States, 2018-2022. MMWR Morb Mortal Wkly Rep. 2024;73(4):70-76. Published 2024 Feb 1. doi:10.15585/mmwr.mm7304a1

Risi M, Greco G, Masciocchi S, et al. MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment. J Neurol. Published online January 27, 2024. doi:10.1007/s00415-024-12180-z

Huang Y, Luo W, Cheng X, et al. Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord. 2024;82:105405. doi:10.1016/j.msard.2023.105405

Rechtman A, Zveik O, Haham N, Freidman-Korn T, Vaknin-Dembinsky A. Thyroid hormone dysfunction in MOGAD and other demyelinating diseases. J Neurol Sci. Published online January 3, 2024. doi:10.1016/j.jns.2024.122866

Gericke FC, Hanson JVM, Hackenberg A, Gerth-Kahlert C. Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Eur J Paediatr Neurol. Published online December 30, 2023. doi:10.1016/j.ejpn.2023.12.006

Nair A, Sankhyan N, Sukhija J, et al. Clinical outcomes and Anti-MOG antibodies in pediatric optic neuritis: A prospective observational study. Eur J Paediatr Neurol. Published online January 17, 2024. doi:10.1016/j.ejpn.2024.01.003

Ren C, Zhou A, Zhou J, et al. Encephalitis is an Important Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Diseases: A Single-Center Cohort Study. Pediatr Neurol. Published online December 28, 2023. doi:10.1016/j.pediatrneurol.2023.12.018

Liyanage G, Trewin BP, Lopez JA, et al. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry. Published online January 30, 2024. doi:10.1136/jnnp-2023-332851

Kurd M, Pratt LT, Gilboa T, et al. Validation of the 2023 international diagnostic criteria for MOGAD in a pediatric cohort. Eur J Paediatr Neurol. Published online January 23, 2024. doi:10.1016/j.ejpn.2024.01.006

Yang Y, Zhang C, Cao C, Su W, Zhao N, Yue W. Clinical Features of Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Isolated Seizure Symptoms. Neuropsychiatr Dis Treat. 2024;20:61-67. Published 2024 Jan 16. doi:10.2147/NDT.S444853

Horiguchi A, Kikuchi K, Horita H, Ogata H, Hamano SI. Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease With Combined Central and Peripheral Demyelination. Pediatr Neurol. Published online December 15, 2023. doi:10.1016/j.pediatrneurol.2023.12.011

George E, Russ JB, Validrighi A, et al. Clinical and Imaging Findings in Children with Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD): From Presentation to Relapse. AJNR Am J Neuroradiol. Published online January 4, 2024. doi:10.3174/ajnr.A8089

Januel E, Brochard V, Le Guennec L, et al. Risk factors and prognosis of orotracheal intubation in aquaporin-4-IgG neuromyelitis optica spectrum disorder attacks. Ann Intensive Care. 2024;14(1):4. Published 2024 Jan 8. doi:10.1186/s13613-023-01213-x

Darole PA, Tayade KS, Uma S, Wadal AR, Patara PP. Recurrent Regional Autonomic Dysfunction as a Presentation of Relapsing Neuromyelitis Optica Spectrum Disorder, Responsive to Ketamine Infusion. Neurol India. 2023;71(6):1247-1249. doi:10.4103/0028-3886.391398

Vlahovic L, McDonald J, Hinman J, et al. Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2024;102(1):e207965. doi:10.1212/WNL.0000000000207965

Carta S, Dinoto A, Capobianco M, et al. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2024;11(1):e200188. doi:10.1212/NXI.0000000000200188

Luo W, Shi Z, Kong L, Wang X, Zhou H. Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study. Eur J Neurol. Published online December 20, 2023. doi:10.1111/ene.16178

de Almeida GMR, de Araujo RS, Castrillo BB, et al. Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil. J Neuroimmunol. Published online January 24, 2024. doi:10.1016/j.jneuroim.2024.578295

San Martin DL, Fukuda TG, Nascimento TS, et al. Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: A cohort study. Mult Scler Relat Disord. Published online January 18, 2024. doi:10.1016/j.msard.2024.105452

Choi UW, Ai X, Li H, Hao Y, Yao X, Guan Y. Immunosuppressive therapy and COVID-19 infection in patients with NMOSD. Immun Inflamm Dis. 2024;12(1):e1128. doi:10.1002/iid3.1128

Wang L, Xia R, Li X, Shan J, Wang S. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD. Front Immunol. 2024;14:1293100. Published 2024 Jan 8. doi:10.3389/fimmu.2023.1293100

Carlsson O, Jonsson DI, Brundin L, Iacobaeus E. Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Single-Center Study. J Clin Med. 2024;13(2):355. Published 2024 Jan 8. doi:10.3390/jcm13020355

Rotstein DL, Freedman MS, Lee L, et al. Predicting time to serologic diagnosis of AQP4+ NMOSD based on clinical factors and social determinants of health. Mult Scler Relat Disord. Published online January 12, 2024. doi:10.1016/j.msard.2024.105434

Akatani R, Chihara N, Koto S, et al. Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study. Immunol Med. Published online January 18, 2024. doi:10.1080/25785826.2024.2304364

Zhang C, Liu R, Gao B, et al. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder. J Neuroimmunol. Published online January 8, 2024. doi:10.1016/j.jneuroim.2024.578285

Weinshenker BG. MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Commentary. Mult Scler. 2024;30(1):23-24. doi:10.1177/13524585231222131

Carnero Contentti E, Wingerchuk DM. MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes. Mult Scler. 2024;30(1):19-21. doi:10.1177/13524585231222132

Marignier R, Cree BA. MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: No. Mult Scler. 2024;30(1):21-23. doi:10.1177/13524585231222140

Pedrosa DA, de Paula Oliveira LKL, Bertanha R, Júnior EA, Fernandes GBP, Thomaz RB. Acute disseminated encephalomyelitis following Saint Louis encephalitis virus infection. Neurol Sci. Published online January 4, 2024. doi:10.1007/s10072-023-07246-1

Liu J, Jin M, Zhang M, Wang Y, Sun S. Multimodal evoked potentials are useful for the diagnosis of pediatric acute disseminated encephalomyelitis. BMC Pediatr. 2024;24(1):92. Published 2024 Feb 2. doi:10.1186/s12887-024-04576-7

Nathani HR, Deodhe NP, Zade RJ, Ratnani GR. Implementation of Multimodal Stimulation and Physical Therapy in Improving the Level of Consciousness and Recovery in Acute Disseminated Encephalomyelitis. Cureus. 2023;15(12):e51217. Published 2023 Dec 28. doi:10.7759/cureus.51217

Jamali Dogahe S, Pakravan P, Pakravan M. Acute Optic Neuritis: An Update on Approach and Management. J Ophthalmic Vis Res. 2023;18(4):433-440. Published 2023 Nov 30. doi:10.18502/jovr.v18i4.14556

If you have a research publication you would like to submit for our next Healthcare Professional Digest issue, please contact Krissy Dilger at [email protected].

CLICK HERE TO GO BACK TO THE 2024 ISSUE 1

Other articles in this issue